Onxeo: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at August 31, 2015


PARIS--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory News:

Onxeo (Paris:ONXEO) (NASDAQ OMX:ONXEO)

Pursuant to article L.233-8 II of the Code de commerce (the French Commercial
Code) and article 223-16 of the Règlement général de l’Autorité des Marchés
Financiers (Regulation of the French stock market authority):

Date       Total           Total number of voting rights
           number of
           outstanding
           shares
August     40, 552,        Theoretical number of voting rights:
31,        083             40, 552, 083
2015                       (including treasury shares)Number of
                           real voting rights: 40, 510, 182
                           (without
                           treasury shares)

At August 31, 2015, the Company’s capital stands at €10,138,020.75.

About Onxeo
Onxeo has the vision to become a global leader and pioneer in oncology, with a
focus on orphan or rare cancers, through developing innovative therapeutic
alternatives to “make the difference”. The Onxeo teams are determined to develop
innovative medicines to provide patients with hope and significantly improve
their lives.

Key products at advanced development stage are:
Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma
Validive® (Clonidine Lauriad®): Positive complete results of the Phase II trial
in severe oral mucositis
Beleodaq® (belinostat): registered in the US in 2nd line treatment of peripheral
T-cell lymphoma
For more information, visit the
website www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3
A 
%2F%2Fwww.onxeo.com&esheet=51173478&newsitemid=0&lan=en
-US&anchor=www.onxeo.com&index=1&md5=906000def4c2565b63c524d38caa138a)
Onxeo
Judith Greciet, CEO
j.greciet@onxeo.com
Nicolas Fellmann, CFO
n.fellmann@onxeo.com
+33 1 45 58 76 00
or
Caroline Carmagnol and Florence Portejoie
+33 6 64 18 99 59 / +33 1 44 54 36 66
onxeo@alizerp.com

Attachments

09034183.pdf